MA55615A - Anticorps humains qui se lient au ret et leurs procédés d'utilisation - Google Patents
Anticorps humains qui se lient au ret et leurs procédés d'utilisationInfo
- Publication number
- MA55615A MA55615A MA055615A MA55615A MA55615A MA 55615 A MA55615 A MA 55615A MA 055615 A MA055615 A MA 055615A MA 55615 A MA55615 A MA 55615A MA 55615 A MA55615 A MA 55615A
- Authority
- MA
- Morocco
- Prior art keywords
- ret
- methods
- human antibodies
- binding human
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962832218P | 2019-04-10 | 2019-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55615A true MA55615A (fr) | 2022-02-16 |
Family
ID=70554175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055615A MA55615A (fr) | 2019-04-10 | 2020-04-09 | Anticorps humains qui se lient au ret et leurs procédés d'utilisation |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220185900A1 (fr) |
EP (1) | EP3953390A1 (fr) |
JP (2) | JP7511576B2 (fr) |
KR (1) | KR20210150509A (fr) |
CN (1) | CN113993898A (fr) |
AU (1) | AU2020270966A1 (fr) |
CA (1) | CA3134258A1 (fr) |
IL (1) | IL287067A (fr) |
MA (1) | MA55615A (fr) |
MX (1) | MX2021012335A (fr) |
WO (1) | WO2020210551A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024503508A (ja) | 2021-01-15 | 2024-01-25 | シージェン インコーポレイテッド | 免疫調節性抗体-薬物コンジュゲート |
AR124812A1 (es) | 2021-02-03 | 2023-05-10 | Seagen Inc | Conjugados y compuestos inmunoestimulantes |
WO2023144790A1 (fr) * | 2022-01-31 | 2023-08-03 | Glaxosmithkline Intellectual Property (No.3) Limited | Prévention et traitement des maux de tête |
WO2023215740A1 (fr) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Conjugués anticorps-médicament immunomodulateurs |
WO2024030577A1 (fr) | 2022-08-03 | 2024-02-08 | Seagen Inc. | Conjugués anti-pd-l1-médicament immunostimulateurs |
EP4321522A1 (fr) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Composés cytotoxiques et conjugués de ceux-ci |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
EP1740946B1 (fr) | 2004-04-20 | 2013-11-06 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
US20090202562A1 (en) | 2005-06-17 | 2009-08-13 | Biogen Idec Ma Inc. | Anti-gfralpha3 antibodies |
JPWO2007049624A1 (ja) | 2005-10-24 | 2009-04-30 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
DK2387583T3 (en) | 2009-01-14 | 2019-01-14 | Ablynx Nv | PULMONAL ADMINISTRATION OF VARIABLE IMMUNGLOBULIN SINGLE DOMAINS AND CONSTRUCTIONS THEREOF. |
MX340541B (es) | 2009-06-05 | 2016-07-13 | Alblynx Nv | Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio. |
MY164121A (en) | 2009-06-26 | 2017-11-30 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
JO3462B1 (ar) * | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
KR101859576B1 (ko) * | 2016-06-30 | 2018-05-18 | 가톨릭대학교 산학협력단 | Kif5b-ret 융합 단백질을 특이적으로 검출하는 항체 및 이의 용도 |
-
2020
- 2020-04-09 KR KR1020217036432A patent/KR20210150509A/ko unknown
- 2020-04-09 JP JP2021559435A patent/JP7511576B2/ja active Active
- 2020-04-09 US US17/602,562 patent/US20220185900A1/en active Pending
- 2020-04-09 MX MX2021012335A patent/MX2021012335A/es unknown
- 2020-04-09 WO PCT/US2020/027554 patent/WO2020210551A1/fr unknown
- 2020-04-09 MA MA055615A patent/MA55615A/fr unknown
- 2020-04-09 CN CN202080042521.7A patent/CN113993898A/zh active Pending
- 2020-04-09 EP EP20724257.9A patent/EP3953390A1/fr active Pending
- 2020-04-09 CA CA3134258A patent/CA3134258A1/fr active Pending
- 2020-04-09 AU AU2020270966A patent/AU2020270966A1/en active Pending
-
2021
- 2021-10-07 IL IL287067A patent/IL287067A/en unknown
-
2024
- 2024-01-11 JP JP2024002528A patent/JP2024024114A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020270966A1 (en) | 2021-10-28 |
WO2020210551A1 (fr) | 2020-10-15 |
KR20210150509A (ko) | 2021-12-10 |
JP2022527373A (ja) | 2022-06-01 |
JP2024024114A (ja) | 2024-02-21 |
JP7511576B2 (ja) | 2024-07-05 |
EP3953390A1 (fr) | 2022-02-16 |
MX2021012335A (es) | 2021-11-12 |
CN113993898A (zh) | 2022-01-28 |
US20220185900A1 (en) | 2022-06-16 |
IL287067A (en) | 2021-12-01 |
CA3134258A1 (fr) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA55615A (fr) | Anticorps humains qui se lient au ret et leurs procédés d'utilisation | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA52390A (fr) | Anticorps anti-coronavirus et procédés d'utilisation | |
MA56074A (fr) | Anticorps contre le sars-cov-2 et leurs procédés d'utilisation | |
MA55025A (fr) | Anticorps anti-trem2 et leurs procédés d'utilisation | |
MA52091A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
MA54615A (fr) | Anticorps monoclonal contre le récepteur alpha de l'interleukine-4 humaine et son utilisation | |
MA46290A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA54594A (fr) | Stéroïdes neuroactifs et leurs procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA43658A (fr) | Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation | |
MA53919A (fr) | Constructions d'acides nucléiques et procédés d'utilisation | |
MA48462A (fr) | Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation | |
MA53328A (fr) | Anticorps anti-siglec-5 et leurs procédés d'utilisation | |
MA49520A (fr) | Agents de comblement tissulaire à base de soie-acide hyaluronique et leurs procédés d'utilisation | |
MA55301A (fr) | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA50501A (fr) | Formulations stables d'anticorps anti-ctla4 seuls et en combinaison avec des anticorps anti-récepteur de mort programmée 1 (pd-1) et leurs procédés d'utilisation | |
MA56165A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA49846A (fr) | Anticorps qui se lient à l'egfr et à cmet |